麻荆止咳颗粒联合莫西沙星治疗成人非重症社区获得性肺炎的药物经济学评价

Pharmacoeconomic evaluation of Majing cough granule combined with moxifloxacin in treatment of adult non-severe community-acquired pneumonia

目的观察院内制剂麻荆止咳颗粒联合莫西沙星注射液治疗非重症社区获得性肺炎(CAP)的疗效和经济性。方法采用回顾性分析,纳入2020年1—12月收治的非重症成人CAP住院患者的病历48例。对照组(n=30)住院期间单独给予莫西沙星注射液,观察组(n=18)在对照组基础上加用麻荆止咳颗粒,比较两组患者治疗前后症状积分改善情况、症状积分总有效率、临床总有效率、成本、CMA比较、敏感性分析、单病种控费受影响程度。结果观察组和对照组治疗前后的症状积分组内比较均有明显改善(P<0.05);但改善程度组间比较,差异无统计学意义(P>0.05);两组临床总有效率分别为94.44%和80.00%,差异无统计学意义(P>0.05);使用最小成本法(CMA)比较显示,观察组成本为7837.46元,低于对照组的9773.78元,观察组有最优性价比;通过敏感性分析,药物成本波动±10%,观察组经济性仍优于对照组(观察组vs.治疗组:-10%,7053.71元vs.8796.40元;+10%:8621.21元vs.10751.16元),分析结果具有一致性。敏感性分析后经济性仍未改变,其经济性对单病种控费无影响(P>0.05)。结论两组疗效相当,观察组经济性更优,但对单病种控费无影响。

Objective To observe the efficacy and economy of the hospital preparation,the Majing cough granule,combined with the moxifloxacin injection in the treatment of non-severe community-acquired pneumonia(CAP).Methods A total of 48 non-severe adult patients with CAP who were hospitalized from January to December 2012 were included in the retrospective analysis.A total of 30 patients in the control group were given the moxifloxacin injection alone during hospitalization,and 18 patients in the observation group were given the Majing cough granule in addition to the control group.The improvement of the symptom score,total response rate of the symptom score,total clinical effective rate,cost,comparison of CMA,sensitivity analysis and degree of influence on the cost control of single disease were compared between the two groups before and after treatment.Results Symptom scores of the observation group and the control group were significantly improved after treatment compared with those before treatment(P<0.05),but no statistically significant difference was observed in the improvement degree between the 2 groups(P>0.05).The total clinical effective rates of the two groups were 94.44%and 80%,respectively,with no statistically significant difference in efficacy(P>0.05).The comparison with the minimum cost method(CMA)showed that the cost of 7837.46 yuan in the observation group was lower than the cost of 9773.78 yuan in the control group,and the observation group had the best cost performance ratio.According to the sensitivity analysis,the drug cost fluctuated by±10%,and the economical efficiency of the observation group was still better than that of the control group(the observation group vs.the treatment group:-10%,7053.71 vs.8796.40 yuan;+10%:8621.21 yuan vs.10751.16 yuan),and the analysis results were consistent.The Economical efficiency remained unchanged after the sensitivity analysis,and had no influence on the cost control of single disease(P>0.05).Conclusion The two groups have similar efficacy,and the economical efficiency of the observation group is better,but it has no effect on the cost control of single disease.